



European Thyroid Association
38th Annual Meeting
Santiago de Compostela, SPAIN | 6-10 September 2014

Scientific Programme/ Wednesday, 10th September

Compostela Room

07.45-08.45 SHORT-CALL ABSTRACTS

Chairpersons: Furio Pacini, Italy; Colin Dayan, United Kingdom

07.45-08.00

WHOLE GENOME SEQUENCE BASED ANALYSIS OF THYROID FUNCTION

Peter N. Taylor^{1*}, Eleonora Porcu^{2,3,4*}, Shelby Chew^{5*}, Purdey J. Campbell^{5*}, Michela Traglia⁶, Suzanne J. Brown⁵, Benjamin H. Mullin^{5,7}, Hashem A. Shihab⁸, Josine L. Min⁸, Klaudia Walter⁹, Yasin Memari⁹, Jie Huang⁹, Michael R. Barnes¹⁰, John P. Beilby^{11,12}, Pimphen Charoen^{13,14}, Petr Daneczek⁹, Frank Dudbridge¹³, Vincenzo Forgetta^{15,16}, Celia Greenwood^{15,16}, Elin Grundberg^{17,18}, Andrew D. Johnson¹⁹, Jennie Hui^{11,12}, Ee M. Lim^{5,11}, Shane McCarthy⁹, Dawn Muddyman⁹, Vijay Panicker⁵, John R.B. Perry^{20,21}, Jordana T. Bell²¹, Wei Yuan²¹, David Schlessinger²², Goncalo Abecasis⁴, Francesco Cucca^{2,3}, Gabriela L. Surdulescu²¹, Wolfram Woltersdorf²³, Eleftheria Zeggini⁹, Houfeng Zheng^{15,16}, Daniela Toniolo^{6,24}, Colin M. Dayan¹, Silvia Naitza², John P. Walsh^{5,7}, Tim D. Spector²¹, George Davey Smith⁸, Richard Durbin⁹, J. Brent Richards^{15,16,21}, Serena Sanna², Nicole Soranzo⁹, Nicholas J. Timpson^{8*}, Scott G. Wilson^{5,7,21*} and the UK10K Consortium²⁵.

* Authors contributed equally.

1) Thyroid Research Group, Institute of Molecular & Experimental Medicine, Cardiff University School of Medicine, Cardiff University, Cardiff, UK; 2) Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari, Italy; 3) Dipartimento di Scienze Biomediche, Università di Sassari, Sassari, Italy; 4) Center for Statistical Genetics, Biostatistics Department, University of Michigan, Ann Arbor, MI, USA; 5) Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; 6) Division of Genetics and Cell Biology, San Raffaele Research Institute, Milano, Italy; 7) School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; 8) MRC Integrative Epidemiology Unit at the University of Bristol, University of Bristol, Bristol, UK; 9) Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK; 10) William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; 11) Pathwest Laboratory Medicine WA, Nedlands, Western Australia, Australia; 12) School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia; 13) Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK; 14) Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 15) Department of Medicine, Jewish General Hospital, McGill University, Montréal Québec, Canada; 16) Departments of Human Genetics, Epidemiology, and Biostatistics, Jewish General Hospital, Lady Davis Institute, McGill University, Montréal Québec, Canada; 17) Department of Human Genetics, McGill University, Montreal, QC H3A1A5, Canada; 18) McGill University and Genome Quebec Innovation Centre, Montreal, QC H3A1A5, Canada; 19) Cardiovascular Epidemiology and Human Genomics Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA; 20) MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK; 21) Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; 22) Laboratory of Genetics, NIA, Baltimore, MD 21224, USA; 23) Facharzt für Laboratoriumsmedizin, Geschäftsführer amedes Ost, Halle/Leipzig GmbH, Leipziger Chaussee 191f, 06112 Halle (Saale), Germany; 24) Institute of Molecular Genetics-CNR, Pavia, Italy

08.00-08.15

EXPOSURE TO HIGH THYROID HORMONE IN UTERO CAUSES PERMANENT REDUCED SENSITIVITY TO THYROID HORMONE

Joao Anselmo¹, Alexandra M. Dumitrescu², Roy E. Weiss³, Samuel Refetoff⁴

¹Serviço de Endocrinologia e Nutrição, Hospital Divino Espírito Santo, 9500-317 Ponta Delgada, Azores-Portugal; ² Department of Medicine, The University of Chicago, Chicago IL, USA; ³Department of Medicine, The University of Miami, Miami FL, USA; ⁴ Departments of Medicine, Pediatrics, and the Committee on Genetics, The University of Chicago, USA

08.15-08.30

TRIAc TREATMENT OF AN INFANT WITH ALLAN-HERNDON-DUDLEY SYNDROME (AHDS): EFFECTS ON IODOTHYRONINES IN SERUM AND CEREBRO-SPINAL FLUID.

Ainhoa Iglesias¹, Olga Esther Alonso², Ana Gómez-Gila³, Juan A. Campos-Cerveró⁴, María Palomares⁵, Eduvigis Contreras⁶, Beatriz Morte⁷, Maria Jesús Obregón⁷, Juan Bernal⁷, José C. Moreno¹.

¹Thyroid Molecular Laboratory. INGEMM. La Paz University Hospital (HULP). Madrid, Spain., ^{2,3}Pediatric Endocrinology and Neurology. Virgen del Rocío Hospital. Sevilla. ⁴Rehabilitation. S. Juan de Dios Hospital. Sevilla. ⁵INGEMM. HULP. ⁶Paidopsychology. HULP. ⁷Institute for Biomedical Research (IIB). CIBERER, CSIC. Madrid, Spain.

08.30-08.45

EFFECTS OF EARLY LT4 TREATMENT IN A PATIENT WITH A MUTATION IN TR α 1/ α 2

Anja L.M. van Gucht¹, Nitash Zwaveling-Soonawala², Marcel E. Meima¹, W. Edward Visser¹, Theo J. Visser¹, Robin P. Peeters¹, A. S. Paul van Trotsenburg²

¹ Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

² Department of Pediatric Endocrinology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands

Compostela Room

08.45-10.15 SYMPOSIUM 7: THYROID HORMONE REPLACEMENT

Chairpersons: Jean Louis Wemeau, France and Francesco Trimarchi, Italy

08.45-09.15 Risks of thyroid hormone replacement

Simon Pearce, United Kingdom

09.15-09.45 Trends in thyroid hormone prescribing, malabsorption and intolerance of thyroid hormone

Salvatore Benvenega, Italy

09.45-10.15 T3 vs T4 therapy

Colin Dayan, United Kingdom

Room 25

08.45-10.15 SYMPOSIUM 8: ADVANCED THYROID TUMORS: STEPS BEFORE TARGET THERAPY

Chairpersons: Laurence Leenhardt, France and Javier Aller Pardo, Spain

08.45-09.15 Outcome of metastatic thyroid cancer

Cosimo Durante, Italy

09.15-09.45 How to detect, to follow-up and to assess target lesions in thyroid cancer

Stéphane Bardet, France

09.45-10.15 Evaluation of the ratio benefices/QoL under TKI treatment

Kate Newbold, United Kingdom

10.15-10.30 COFFEE BREAK

Compostela Room

10.30-12.30 ORAL SESSION 12: THYROID CANCER THERAPY (OP87-OP94)

Chairpersons: Rossella Elisei, Italy and Garcilaso Riesco-Eizaguirre, Spain

10.30-10.45

OP87 EXPLORATORY ANALYSIS OF OUTCOMES FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-RDTC) RECEIVING OPEN-LABEL SORAFENIB POST-PROGRESSION ON THE PHASE III DECISION TRIAL

Martin Schlumberger¹, Christopher Nutting², Barbara Jarzab³, Rossella Elisei⁴, Salvatore Siena⁵, Lars Bastholt⁶, Christelle de la Fouchardiere⁷, Furio Pacini⁸, Ralf Paschke⁹, Young Kee Shong¹⁰, Steven I Sherman¹¹, Johannes WA Smit¹², John Chung¹³, Christian Kappeler¹⁴, Istvan Molnar¹³, Marcia S Brose¹⁵

¹Gustave Roussy; ²Royal Marsden Hospital; ³Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology
⁴Department of Clinical and Experimental Medicine, University of Pisa; ⁵Ospedale Niguarda Ca' Granda; ⁶Odense University Hospital; ⁷Consortium Cancer Thyroïdien, Hospices Civils-Centre Anticancéreux; ⁸Unit of Endocrinology, University of Siena
⁹Department for Endocrinology and Nephrology, Leipzig University; ¹⁰Asan Medicine Center, University of Ulsan College of Medicine; ¹¹The University of Texas MD Anderson Cancer Center; ¹²Department of Internal Medicine, Radboud University Medical Center; ¹³Bayer Healthcare Pharmaceuticals; ¹⁴Bayer Pharma AG; ¹⁵Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania

10.45-11.00

OP88 FOLLICULAR (FVPTC) VS CLASSICAL (CVPTC) VARIANT OF PAPILLAR THYROID CANCER: CORRELATION OF THE OUTCOME AFTER 12 YEARS OF FOLLOW UP

Carlotta Giani¹, Liborio Torregrossa², Eleonora Molinaro¹, Andrea Cacciato Insilla², Laura Agate¹, David Viola¹, Luciana Puleo¹, Gabriele Materazzi², Ivo Marchetti³, Paolo Miccoli², Giancarlo Di Coscio³, Paolo Vitti¹, Fulvio Basolo², Rossella Elisei¹

¹Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
²Department of Surgical, Medical and Molecular Pathology of the Clinical Area, University of Pisa, Pisa, Italy
³Department of Translational Research and New Technologies in Medicine and Surgeons, University of Pisa, Pisa, Italy

11.00-11.15

OP89 CONSERVATIVE VS RADICAL SURGICAL MANAGEMENT IN CHILDREN WITH DIFFERENTIATED THYROID CANCER: MULTICENTRIC STUDY

Claudio Spinelli¹, Paolo Miccoli¹, Alessandro Inserra², Gianni Bisogno³, Giovanni Cecchetto³, Poupak Fallahi¹, Alessandro Antonelli⁰

¹University of Pisa; ²"bambino Gesù" Pediatric Hospital; ³University of Padova, Italy

11.15-11.30

OP90 PROGNOSTIC VALUE OF MICROSCOPIC LYMPH NODE INVOLVEMENT IN PATIENTS WITH PAPILLARY THYROID CANCER

Stephane Bardet¹, Renaud Ciappuccini¹, Elske Quak¹, Jean-Pierre Rame¹, David Blanchard¹, Dominique De Raucourt¹, Emmanuel Babin², Jean-Jacques Michels¹, Dominique Vaur¹, Natacha Heutte³

¹Centre Francois Baclesse; ²Chu; ³Université de Basse-Normandie, France

11.30-11.45

OP91 METASTATIC THYROID CANCER UNRESPONSIVE TO CONVENTIONAL THERAPY TREATED WITH SORAFENIB "OFF-LABEL": AN UPDATE OF OUR 6 YEARS OF EXPERIENCE

Virginia Cappagli¹, Valeria Bottici¹, Eleonora Molinaro¹, Laura Agate¹, David Viola¹, Laura Valerio¹, Paolo Piaggi², Salvatore Mazzeo³, Valentina Battaglia³, Benedetta Pontillo Contillo³, Paolo Vitti¹, Rossella Elisei¹

¹Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ²Department Of Energy and Systems Engineering, University of Pisa; ³Department for Integrated Activity Radiology, Vascular and Interventional Radiology, Nuclear Medicine; University of Pisa, Pisa, Italy

11.45-12.00

OP92 DIFFERENTIAL GENE EXPRESSION IN FOLLICULAR THYROID CARCINOMAS SHOWING DIFFERENT DEGREES OF INVASIVENESS

Ricardo Celestino¹, Torfinn Nome², Ana Pestana³, Eva Sigstad⁴, Ragnhild A. Lothe⁵, Trine Bjørø⁶, Manuel Sobrinho-Simões⁷, Rolf I. Skotheim², Paula Soares⁸

¹Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; School of Allied Health Sciences Estsp, Polytechnic of Porto, Porto, Portugal; ²Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Institute of Biomedical Sciences of University of Porto, Porto, Portugal; ⁴Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; ⁵Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Molecular Biosciences, University of Oslo, Oslo, Norway; ⁶Department of Medical Biochemistry, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ⁷Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Medical Faculty, University of Porto, Porto, Portugal; Department of Pathology, Centro Hospitalar de São João, Porto, Portugal ⁸Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Medical Faculty, University of Porto, Porto, Portugal

12.00-12.15

OP93 SURGICAL STRATEGY IN LOW ADVANCED DIFFERENTIATED THYROID CANCER STAGED T1N0M0 - RESULTS OF A PILOT FEASIBILITY STUDY

Agnieszka Czarniecka¹, Stanislaw Poltorak¹, Aleksander Sacher¹, Adam Maciejewski¹, Jolanta Krajewska¹, Michal Jarzab¹, Ewa Stobiecka¹, Ewa Zembala-Nozynska¹, Ewa Chmielik¹, Dagmara Rusinek¹, Monika Kowal¹, Malgorzata Oczko-Wojciechowska¹, Daria Handkiewicz-Junak¹, Barbara Jarzab¹

¹Centre of Oncology M.Sklodowska-Curie Memorial Institute Gliwice Branch, Poland

12.15-12.30

OP94 PERCUTANEOUS TREATMENT OF BONE METASTASES FROM DIFFERENTIATED THYROID CARCINOMAS: RESULTS FROM A COHORT OF 23 PATIENTS

Françoise Bonichon⁰, Cazzato Roberto Luigi¹, Buy Xavier², Godbert Yann³, Henriques de Figueiredo Bénédicte⁴, Pointillart Vincent⁵, Palussiere Jean⁶

¹Dept of Diagnostic Imaging and Interventional Radiology Università Campus Bio-Medico DI Roma Via Alvaro del Portillo, 200 Rome; ²Department of Interventional Radiology, Institut Bergonié, 229 Cours de L'argonne, 33076, Bordeaux Cedex, France; ³Department of Nuclear Medicine, Institut Bergonié, 229 Cours de L'argonne, 33076, Bordeaux Cedex, France ⁴Department of Radiotherapy, Institut Bergonié, 229 Cours de L'argonne, 33076, Bordeaux Cedex, France ⁵Spinal Surgery Unit, Department of Orthopaedics, University Hospital of Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France; ⁶Department of Interventional Radiology, Institut Bergonié, 229 Cours de L'argonne, 33076, Bordeaux Cedex, France,

Room 25

10.30-12.30 ORAL SESSION 13: GENE EXPRESSION (OP95-OP102)

Chairperson: Riccardo Zucchi, Italy and Joao Anselmo, Portugal

10.30-10.45

OP95 THE TRANSCRIPTION FACTOR NRF2 CONTROLS ANTIOXIDANT RESPONSES AND IMPACTS THYROID-SPECIFIC GENE EXPRESSION AND HANDLING OF EXCESS IODINE

Panos Ziros¹, Ioannis Habeos², Dionysios Chartoumpeki³, Michail Mpakakis², Irene Mamali², Stavroula Manolakou¹, Ioannis Lilis², Nikolaos Papachristou², Venetsana Kyriazopoulou², Thomas Kensler³, Dionysios Papachristou², Gerasimos Sykiotis¹

¹Lausanne University Hospital

²University of Patras Medical School

³University of Pittsburgh

10.45-11.00

OP96 THE NUCLEAR COREPRESSOR NCOR IS AN ESSENTIAL MEDIATOR OF THE ANTI-TUMORIGENIC AND ANTI-METASTATIC ACTIONS OF THE THYROID HORMONE RECEPTOR β

Olaia Martinez-Iglesias¹, Rosa Martin-Orozco¹, Elvira Alonso-Merino¹, Juan Pedro Velasco-Martín², Javier Regadera², Jose Palacios³, Pilar González-Peramato⁴, Ana Aranda¹

¹Instituto de Investigaciones Biomédicas; ²Universidad Autónoma de Madrid; ³Hospital Ramón Y Cajal; ⁴Hospital La Paz

11.00-11.15

OP97 BEHAVIORAL AND METABOLIC EFFECTS OF 3-IODOTHYROACETIC ACID: ROLE OF HISTAMINE

Maria Elena Manni¹, Alessandro Saba², Annunziatina Laurino¹, Riccardo Donzelli², Grazia Chiellini², Riccardo Zucchi², Laura Raimondi¹

¹University of Florence; ²University of Pisa, Italy

11.15-11.30

OP98 IDENTIFICATION OF AN INTRA-MOLECULAR DISULFIDE BRIDGE ESSENTIAL FOR THE COVALENT AND FUNCTIONAL INTERACTION BETWEEN DUOX2 AND ITS PARTNER DUOX2

Carré Aurore¹, Louzada Ruy², Ameziane El Hassani Rabii³, Corinne Dupuy⁰

¹Université Paris-Sud 11; Umr 8200 Cnrs; Institut Gustave Roussy

²Laboratório de Fisiologia Endócrina Doris Rosenthal; Universidade Federal Do Rio de Janeiro

³Ubrm, Centre National de L'énergie, des Sciences Et des Techniques Nucléaires, Rabat,

11.30-11.45

OP99 THYROID HORMONES REDUCE THE TGFB-DEPENDENT ACTIONS, ALLEVIATING FIBROTIC RESPONSES

Elvira Alonso-Merino¹, Rosa Martin-Orozco¹, Lidia Ruíz Llorente¹, Luis Fernanda Fanjul Rodríguez¹, Olaia Martinez-Iglesias¹, Juan Pedro Velasco-Martín², Javier Regadera², Ana Aranda¹

¹Instituto de Investigaciones Biomédicas

²Universidad Autónoma de Madrid

11.45-12.00

OP100 THYROMIMETIC ACTION OF 3,5-T2 IN DIET-INDUCED OBESE MICE

Julika Lietzow¹, Wenke Jonas², Priyavathi Dhandapani¹, Josef Köhrle¹

¹Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany

²German Institute of Human Nutrition (Dife), Nuthetal, Germany

12.00-12.15

OP101 SELENIUM INCREASES THYROTROPHIN-INDUCED NIS EXPRESSION THROUGH APE1-DEPENDENT REGULATION OF PAX8 BINDING ACTIVITY

Suzana Leoni¹, Ana Sastre-Perona², Pilar Santisteban¹, Antonio De la Vieja³

¹Instituto de Investigaciones Biomédicas (Csic-Uam); ²Instituto de Investigaciones Biomédicas (Csic-Uam) - Madrid

³Instituto de Salud Carlos III (Área de Biología Celular Y Desarrollo, Centro Nacional de Microbiología), Spain

12.15-12.30

OP102 3-IODOTHYROACETIC ACID INDUCES GENERALIZED ITCH AND HYPERSENSITIVITY TO NOXIUS HEAT STIMULI IN MOUSE

Annunziata Laurino¹, Francesco Resta¹, Riccardo Zucchi², Laura Raimondi¹

¹University of Florence; ²University of Pisa, Italy

Compostela Room

12.30-13.00 YOUNG INVESTIGATOR AWARDS, ETA POSTER PRIZES, JACK ROBBINS PRIZE AND CLOSING CEREMONY

President, Furio Pacini, Italy & Secretary, Colin Dayan, United Kingdom